Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bracco's MultiHance market position in Germany - correction:

This article was originally published in Clinica

Executive Summary

In Clinica No 1136 (December 10 2004), we stated erroneously on page 20 that Bracco Diagnostics in the US (which is the Princeton, New Jersey branch of Milan, Italy-based Bracco SpA) claimed in a press briefing that its MultiHance MRI contrast agent, which provides improved visualisation of CNS lesions, was the market leader in Germany. What Bracco's head of WM medical affairs Dr Alberto Spinazzi actually said was "Bracco has two MR contrast agents approved in Germany (ProHance and MultiHance)-and together these two products enjoy a significant market share in Germany."

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel